HLA-A*1101 & B2M & HPV16-E6 (TTLEQQYNK) Product List
Species
- Human（1）
Tag
- His Tag（1）
Host
- HEK293（1）
Conjugate
- PE Labeled（1）
Grade
- RUO（1）
Low Endotoxin
- No（1）
| Molecule | Cat. No. | Product Name | Species | Host | Structure | Purity | Activity | Size&Price |
|---|---|---|---|---|---|---|---|---|
| HLA-A*1101 & B2M & HPV16-E6 (TTLEQQYNK) | PE-Labeled Human HLA-A*11:01&B2M&HPV16-E6 (TTLEQQYNK) Tetramer Protein |  Human | HEK293 | $410.00 25ug |
You Have Viewed 1-1 Of 1 Results
Asset Licensing Opportunity
Resources
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Mavrilimumab | CAM-3001; KPL-301; GM-CSFR; CAM3001 | Phase 3 Clinical | Csl Ltd | Pneumonia; Giant Cell Arteritis; Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19) | Details |
| CSF2RA gene-corrected macrophages(University of South Florida) | Phase 2 Clinical | Russian Academy Of Medical Sciences | Pulmonary Alveolar Proteinosis | Details | |
| STSA-1005 | STSA-1005; STSA1005 | Phase 1 Clinical | Coronavirus Disease 2019 (COVID-19) | Details |
Customer Reviews